[Corrections] Correction to Lancet Neurol 2019; 18: 329–31

21:41 EDT 8 Jul 2019 | The Lancet

Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol 2019; 18: 329–31—In this Correspondence, Christina Azevedo and coauthors stated: “We have retrospectively identified another five cases of spontaneous intracranial haemorrhage that occurred during the initial 5-day course of alemtuzumab administration.” With the use of the word “another”, the statement implied that the five cases of intracranial haemorrhage described in their letter were in addition to 13 cases that had been reported to the FDA.

Original Article: [Corrections] Correction to Lancet Neurol 2019; 18: 329–31


More From BioPortfolio on "[Corrections] Correction to Lancet Neurol 2019; 18: 329–31"

Quick Search


Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...